2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)

EUROPEAN HEART JOURNAL

Volume 43, Issue 41, Pages 4229-4361

OXFORD UNIV PRESS

Guidelines; Androgen deprivation therapy; Anthracycline; Atrial fibrillation; Arrhythmias; Biomarkers; Cancer; Cancer survivors; Carcinoid syndrome; Amyloid light-chain cardiac amyloidosis; Cardiac magnetic resonance; Cardiac tumour; Cardio-oncology; Cardiotoxicity; Coronary artery disease; Chemotherapy; Echocardiography; Fluoropyrimidine; Heart failure; Haematopoietic stem cell transplantation; Hormone therapy; Hypertension; Immunotherapy; Ischaemic heart disease; Myocarditis; Pericardial disease; Pulmonary hypertension; Thrombosis; Risk stratification; Trastuzumab; Valvular heart disease; Vascular endothelial growth factor inhibitors (VEGFi); Venous thromboembolism; Pericardial disease; Proteasome inhibitors; QTc prolongation; Radiotherapy; Strain

Cardiac & Cardiovascular Systems